Yup. There is that. But then again, by the time a vaccine is developed I wonder how many first responder and medical workers there will be that do not test positive for antibodies already. So there is that as well. Either way, your point would be the same as mine - ie. there are populations already where we know they should go firstest and mostest. Just do that for starters.
The US would be the first to get a potential coronavirus vaccine being created by a French company, its CEO said https://www.businessinsider.com/pot...first-french-pharmaceutical-sanofi-ceo-2020-5 The US would be first country to get a potential coronavirus vaccine if it's successfully made by French pharmaceutical company Sanofi. Because the US "invested in taking the risk" first, it would also be first to receive the vaccine, Sanofi CEO Paul Hudson told Bloomberg News. The comments raise questions about how distribution would be handled once a vaccine is created. The US would be the first to receive a potential coronavirus vaccine if French pharmaceutical company Sanofi is able to produce it. Sanofi CEO Paul Hudson told Bloomberg that "the US government has the right to the largest pre-order because it's invested in taking the risk." He said that the United States was first to fund the company's research, so it expects "that if we've helped you manufacture the doses at risk, we expect to get the doses first." After receiving a boost from the US in February, Sanofi has partnered on the search for a vaccine with British pharmaceutical company GlaxoSmithKline. The European companies' research is among over 100 efforts to find a vaccine for the coronavirus. The comments from Sanofi are likely to rekindle questions over how a potential vaccine would be distributed. Experts have told Business Insider that without a concrete plan for distribution, chaos could ensue. Inside the US, some have suggested prioritizing healthcare workers as the first to receive the vaccine. But distributing the vaccine on a global scale will likely be complicated by politics and logistics. In a statement to Business Insider, Sanofi said that the company is committed to making its vaccine "accessible to everyone" and that it has manufacturing capabilities in the United States, Europe, and other parts of the world. Vaccines would be distributed in areas where they are produced, the company said. Sanofi's partnership with the US "allows [us] to initiate production as early as possible while we continue to develop and register the vaccine." Hudson told Bloomberg he is pushing European leaders to invest more in a vaccine, saying that the region could be left behind as other countries pursue vaccine research through funding. The French Embassy in Washington referred Business Insider to the French Health Ministry, which did not immediately respond to a request for comment. "I've been campaigning in Europe to say the US will get vaccines first," Hudson said. "That's how it will be because they've invested to try and protect their population, to restart their economy." Sanofi said in its statement that it is "very encouraged to see the mobilization of the EU Commission over the past weeks" and that the company is having "very constructive conversations with the EU institutions and the French and German government amongst others."
France says the U.S. does not get the vaccine first... Let's send a small naval ship over -- I'm sure they would surrender. France: No, the U.S. Will Not Get First Access to Any French-Made Vaccine https://www.thedailybeast.com/franc...t-get-first-access-to-any-french-made-vaccine France has shot down the prospect of the United States getting its hands on a French-made vaccine before anyone else. It was reported earlier this week that the U.S. will likely be first in line to roll out any successful vaccine made by French company Sanofi because America was the first to fund the firm’s research. However, Bloomberg News reports that the French government has balked at that suggestion, setting up a conflict if a successful vaccine is developed. “For us, it would be unacceptable that there be privileged access for this or that country on a pretext that would be a financial pretext,” Junior Economy Minister Agnes Pannier-Runacher said Thursday. Olivier Bogillot, the head of Sanofi France, said: “It’s evident that if Sanofi discovers a medicine, a vaccine against COVID-19 and if it’s effective, it will be available to all.” Read it at Bloomberg News
Everyone keeps saying that we are at war with this virus thing. Now we are being told that we have put the French in charge. What could go wrong there?
Results From Oxford University's Human Trial Of Coronavirus Vaccine Could Arrive In June; Where Inovio, Moderna Stand https://www.benzinga.com/general/bi...avirus-vaccine-could-arrive-in-june-where-ino The University of Oxford, which is partnering with large-cap pharma AstraZeneca plc AZN 0.02% to develop a vaccine for SARS-CoV-2, could lead the pack in advancing its vaccine candidate to the next stage. The university is one of the eight companies and institutions that have advanced their candidates to human testing, according to the latest World Health Organization statistics. Phase 1 Results In Mid-June About 1,000 people have been vaccinated in the first phase of the vaccine program, which is going as planned and without safety scares, Prof. John Bell, regius professor of medicine at the Oxford University, reportedly told BBC Radio 4's Today program. Results of the Phase 1/2 trial that is underway could be available by mid-June, Bell said. "We also want to make sure that the rest of the world will be ready to make this vaccine at scale so that it gets to populations in developing countries, for example, where the need is very great." Oxford University's Coronavirus Vaccine Program The university first announced in mid-March that it shortlisted a chimpanzee adenovirus vaccine vector developed at its Jenner Institute as the most suitable vaccine candidate. The candidate was named as ChAdOx1 nCoV-19. About a week later, the university said it would enroll healthy volunteers ages 18-55 to test the vaccine candidate and assess its immune response. The initial target for enrollment was 510 volunteers who would receive either the vaccine candidate or a control injection. The university announced April 24 that it began testing the vaccine candidate in a study with about 1,100 people. On April 30, the university announced an agreement with AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate. Moderna, Inovio's Programs Moderna Inc MRNA is targeting a second-quarter start for a planned Phase 2 study that's been approved by the FDA. However, the beginning of the study is contingent on positive results from the NIAID-sponsored Phase 1 study. This suggests the Phase 1 results could be available later this month or June. Moderna is planning for a Phase 3 study initiation in early summer. Meanwhile, Inovio Pharmaceuticals Inc INO has suggested summer timeline for the start of a Phase 2/3 study and is now conducting a Phase 1 study.
Trump unveils new vaccine effort https://edition.cnn.com/2020/05/15/politics/trump-vaccine-effort-coronavirus/index.html President Donald Trump, whose prediction of a coronavirus vaccine by year's end outpaces the outlook given by most health officials, announced the two men leading his "Operation Warp Speed" development effort during a noon event in the Rose Garden on Friday. "We'd love to see if we could do it prior to the end of the year," Trump said as he unveiled the project. "Operation Warp Speed," Trump said, "means big and it means fast." CNN reported earlier this week that Trump was naming Moncef Slaoui, the ex-head of GlaxoSmithKline's vaccines division, to lead the effort alongside four-star Army General Gustave Perna. Slaoui, who has been a venture capitalist since leaving the pharmaceutical giant in 2017, will act as the chief adviser to the vaccine effort. Perna will serve as the chief operating officer overseeing logistics, White House officials said. Trump said this week he would "rapidly" mobilize the military to distribute a vaccine when it is ready. Both men supplement the vaccine development efforts already underway by the federal government, including at the National Institutes of Health. A leader at that agency, Dr. Anthony Fauci, also attended Friday's event in the Rose Garden. A top White House adviser during the coronavirus pandemic, Fauci has recently come under fire by some of Trump's allies for his caution on reopening the country, which he said would have grave consequences if not done carefully. Fauci, whose testimony before a Senate committee earlier this week drew a rebuke from Trump, has not appeared alongside the President at the White House since April 29, when he delivered some good news on promising results of remdesivir clinical trials during a meeting in the Oval Office with Louisiana Gov. John Bel Edwards. However, he has been spotted at the White House multiple times, including in a Tuesday meeting with Vice President Mike Pence and other task force members. Fauci, like other health experts, has warned that developing a vaccine could take a year at minimum and potentially much longer. He said during his testimony this week it was unlikely a vaccine would be developed in time for students to return to school in the fall. Trump has been more bullish. On Thursday, he predicted a vaccine would be developed by the end of 2020. "We're going to have a lot of good things happen. We have a lot of great people working on it," he said in an interview with the Washington Examiner. "We're going to have a lot of good things, therapeutically and with a vaccine. And I think you'll have it by the end of the year." Previewing the noon event to reporters Friday morning, Trump adviser Kellyanne Conway said Trump would also tout efforts already underway by the federal government to develop a vaccine. "He'll be unveiling two professionals leading the effort, but that comes very quickly on the heels of the (Food and Drug Administration) cutting a ton of red tape and regulations to allow us to already be developing vaccines," Conway said. "Today he will talk about health professionals and the military, and others (in) the private sector (and) public sector, (who) will be fully engaged in the development of this vaccine, at warp speed," Conway continued. The White House tapped Slaoui to lead the "Warp Speed" vaccine project after interviewing four candidates, according to a senior administration official. Health and Human Services Secretary Alex Azar, senior adviser Jared Kushner, adviser Adam Boehler, Dr. Deborah Birx, Deputy Secretary of Defense David Norquist, HHS deputy chief of staff Paul Mango and Fauci all participated in the interview process. The decision to select Slaoui was "unanimous" and apparent to all of the administration panelists during the interview with Slaoui, the senior administration official said. Slaoui met with Trump at the White House on Wednesday, the official said, and Trump signed off on his selection after getting the unanimous nod from his team. Slaoui "feels confident" about the administration's goal of delivering a Covid-19 vaccine by January, the official said, and is "very optimistic" about the prospects of success for the development of a vaccine. Slaoui's primary mission will be to determine which vaccines to bet on as the administration moves to manufacture more than one vaccine before trials are completed. Two of the other candidates were Elias Zerhouni and Mark McClellan, the former Centers for Medicare & Medicaid Services director under President George W. Bush. Slaoui has held seats on the boards of multiple corporations pursuing a coronavirus vaccine, including Moderna. A person familiar with the matter said Slaoui would vacate his seats upon assuming his role in the vaccine effort. Scientists who are part of the Trump administration's coronavirus vaccine project have identified 14 vaccines to focus on for development, according to a senior administration official. Those involved in the effort expect to have six to eight of the vaccines being tested make it to subsequent rounds of trials, the official said. Officials hope to have three to four vaccines make it through final testing and be made available, but that depends on how the testing and clinical trials proceed and how successful they are. The HHS division tasked with vaccine development, BARDA, has seen its leadership in flux after the former director Dr. Rick Bright was ousted. Bright filed a formal whistleblower complaint alleging his early warnings about the coronavirus were ignored and that his concerns about promoting an untested therapeutic heralded by the President led to his removal. He testified on Capitol Hill Thursday that 18 months may be an unrealistic goal for developing a vaccine. "There is a lot of optimism. There is a lot of hope," Bright said in his testimony. "But that doesn't make a vaccine. There's a lot of work that needs to be done to make a vaccine."
Trump promises coronavirus vaccine by end of the year, but his own experts temper expectations A vaccine has never been developed so quickly. https://abcnews.go.com/Politics/tru...ine-end-year-experts-temper/story?id=70712823 President Donald Trump is doubling down on his claim that Americans could see a vaccine for the novel coronavirus by the end of the year. "Another essential pillar of our strategy to keep America open is the development of effective treatments and vaccines as quickly as possible. I want to see if we can do that very quickly," Trump said Friday at an event to highlight his administration's effort to expedite a vaccine, dubbed "Operation Warp Speed." "When I say 'quickly,' we're looking to get it by the end of the year if we can. Maybe before." But the Trump administration's own medical and scientific experts leading the race to develop a vaccine routinely cast doubt on that timeline. On Friday, the president tapped Moncef Slaoui, a former pharmaceutical executive, to lead Operation Warp Speed. Even he concedes the goal is formidable. "Frankly, 12-18 months is already a very aggressive timeline," Slaoui, the former CEO of GlaxoSmithKline, said in an interview with The New York Times. He said he was in agreement with Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Disease, about the challenge that timeline poses. Still, Slaoui, the former CEO of GlaxoSmithKline, did say mass producing a vaccine by January 2021 is a "credible objective." Slaoui maintained he would not have agreed to head up the White House's effort if he did not think Trump's goals were attainable. Since the beginning of the coronavirus crisis, Fauci has frequently cited the 12- to 18-month timeline. He delivered a reality check at a Senate hearing Tuesday when he said having a vaccine for the start of the next school year is not possible. "Even at the top speed we're going, we don't see a vaccine playing in the ability of individuals to get back to school this term," Fauci said. But when Sen. Mitt Romney, R-Utah, pressed Fauci on the likelihood of developing a vaccine within in a year or two, Fauci was said it's "not a long shot." "I think it's clearly much more likely than not that somewhere within that time frame we will get a vaccine for this virus," he said. But Dr. Rick Bright, the former head of the Biomedical Advanced Research and Development Authority, emphasized to the House Energy and Commerce's Subcommittee on Health Thursday that such a timeline would be unprecedented. "Normally it takes up to 10 years to make a vaccine. We've done it faster in emergency situations, when we had starting material in the freezer for Ebola, but for a novel virus, this actually hasn't been done yet that quickly," Bright said. "A lot of optimism is swirling around a 12- to 18-month time frame. If everything goes perfectly -- we have never seen everything go perfectly. "I still think 12 to 18 months is an aggressive schedule, and I think it's going to take longer than that to do so." On Friday, Defense Secretary Mark Esper echoed the president's claims that the vaccine will be ready in record time. "We will deliver by the end of this year a vaccine, at scale, to treat the American people and our partners abroad," Esper vowed at the "Operation Warp Speed" event. But the Pentagon's chief spokesperson, Jonathan Hoffman, told reporters hours later that the timeline is more like a goal than a certainty. "You set a goal, you have confidence that you're going to put the resources to it to obtain that goal. And I think that's what the secretary, that's what the president, are saying is that we have a goal," Hoffman said. Currently there are more than 100 vaccines being studied, and at least eight of those have already progressed outside the laboratory and into human studies, according to the World Health Organization. The furthest along include candidates from the University of Oxford, Pfizer, Moderna Therapeutics, Inovio Pharmaceuticals and China's CanSino Biologics. Many of these vaccines use different technology -- some new to vaccine science -- and experts still don't know which is the most likely to work. Other experts interviewed by ABC News have agreed with Bright, saying that developing a vaccine within a 12-month time frame could mean throwing normal scientific standards out the window, but added that a vaccine could be available by the new year if everything goes perfectly. "It is not impossible," said Paul Duprex, Ph.D., director of the Center for Vaccine Research and professor of microbiology and molecular genetics at the University of Pittsburgh. "It's of course very aggressive -- but it is possible." "You'd have to be lucky," said Dr. Paul Offit, co-inventor of the rotavirus vaccine, who sits on the Food and Drug Administration's vaccine advisory committee. "It would be remarkable, but not completely ridiculous." Bright also warned Thursday of potential supply chain shortages for necessary materials like vials, needles and syringes, as well as the buffers and solutions used to make the vaccine. Bright highlighted the importance of a plan to distribute the vaccine, given enough doses for every American will not be ready at once. Creating that plan is one of the goals of Operation Warp Speed. "If you can imagine this scenario this fall or winter or maybe early next spring when vaccine becomes available; there is no one company that that can produce enough for our country and for the world," Bright said. "It's going to be limited supplies. We need to have a strategy and plan in place now to make sure we can not only fill that vaccine, make it, distribute it, but administer it in a fair and equitable plan." Trump said Friday his administration is working on a plan to distribute the vaccine, including ramping up production of necessary materials and supplies. The president even mentioned on Thursday the military could be involved in the effort to dispense the vaccine. "Operation Warp Speed is also making the necessary preparations to distribute these lifesaving treatments at scale. So, we are talking about massive numbers, so that millions of Americans will quickly have access to them," Trump said. Efforts are already underway to mass produce vaccines that are still being studied, in an attempt to have doses ready to be administered as soon as possible. "We're going to make production at risk, means we'll start putting hundreds of millions of dollars of federal government money into the development and production of vaccine doses before we even know it works. So that when we do ... ultimately get an effective and safe vaccine, that we will have doses available to everyone who needs it in the United States," Fauci said Tuesday.
Why optimism over a coronavirus vaccine might be misplaced https://finance.yahoo.com/news/why-...rus-vaccine-might-be-misplaced-200442654.html As COVID-19 infections rise worldwide, pharmaceutical companies working on coronavirus vaccines have floated promising — and sometimes aggressive — timelines for regulatory approval. However, it’s highly unlikely that any treatment will see the light of day in 2020, given that the availability of those currently under development will be dedicated solely to emergency use. Hopes for an effective treatment are building alongside expectations that more states can gradually relax the stay-at-home orders decimating the economy. Yet in a Senate hearing this week, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), reiterated his belief that a vaccine in time for the Fall school term is unlikely. Back in March, Fauci said that, at best, the industry will find a “signal of efficacy” by the fall. ”And an efficacy signal means that even though you haven’t definitively proven that a vaccine works, you get enough information that if it were an emergency, you might be able to have an emergency use authorization for it,” Fauci said at a March 31 briefing. Still, even with dozens of companies furiously at work on a vaccine, health care professionals say 2021 is the more reasonable timeframe — and that’s if everything goes perfectly. “We’ve never seen everything go perfectly,” said Dr. Rick Bright, the whistle-blowing former BARDA director who was in charge of developing vaccines for the coronavirus. “I think it’s going to take a lot longer than that,” he told a Congressional hearing on Wednesday. In addition, production remains a major concern. “Normally it takes up to 10 years to make a vaccine. We’ve done it faster in emergency situations...when we had starting material in the freezer for Ebola,” Bright added. “But for a novel virus, it actually hasn’t been done quickly.” The breakthrough success of Gilead Sciences’s (GILD) remdisivir, an experimental antiviral treatment that’s receiving emergency use authorization from the FDA, is an example of why expectations for an accelerated timeline for a vaccine are so problematic. In Gilead’s case, there are only 1.5 million doses available, which the company has pledged to donate. However, the distribution plan has already run into trouble, with some states and hospitals left empty-handed amid a confusing prioritization method. The company has signed voluntary licensing deals with five generic manufacturers to help meet the demand in 127 countries — and is not collecting royalties on the drugs until a vaccine is found or until the World Health Organization rescinds the global health emergency designation for the coronavirus. The level of unprecedented demand — which will require several billion doses — is also a major concern for vaccine makers. With government and non-profit help, they are ramping up doses of their unproven vaccine candidates. When one does become available, “there’s no one company that can produce enough for our country or for the world. It’s going to be limited supplies,” Bright told lawmakers this week. “We need to have a strategy and plan in place now to make sure we can not only build that vaccine, make it, distribute it, administer it, in a fair and equitable plan. We don’t have that yet and it is a significant concern,” he added. already run into trouble, with some states and hospitals left empty-handed amid a confusing prioritization method.">In Gilead’s case, there are only 1.5 million doses available, which the company has pledged to donate. However, the distribution plan has already run into trouble, with some states and hospitals left empty-handed amid a confusing prioritization method. The company has signed voluntary licensing deals with five generic manufacturers to help meet the demand in 127 countries — and is not collecting royalties on the drugs until a vaccine is found or until the World Health Organization rescinds the global health emergency designation for the coronavirus. The level of unprecedented demand — which will require several billion doses — is also a major concern for vaccine makers. With government and non-profit help, they are ramping up doses of their unproven vaccine candidates. When one does become available, “there’s no one company that can produce enough for our country or for the world. It’s going to be limited supplies,” Bright told lawmakers this week. “We need to have a strategy and plan in place now to make sure we can not only build that vaccine, make it, distribute it, administer it, in a fair and equitable plan. We don’t have that yet and it is a significant concern,” he added.
I'm guessing since the symptoms are like the flu its like the flu,just a guess though.After I get the flu I don't get it again for another 2-5 years but I eventually get it again.I'm guessing this might be the same but GWB is posting articles showing you can get it weeks later after having it the first time.Since I got over it Ive been living with taking no covid precautions what so ever and haven't gotten sick again.